ABRAMS' tCLINICAL tDRUG tTHERAPY: tRATIONALES tFOR tNURSING tPRACTICE
,ABRAMS' tCLINICAL tDRUG tTHERAPY: tRATIONALES tFOR tNURSING
tPRACTICE
,ABRAMS' tCLINICAL tDRUG tTHERAPY: tRATIONALES tFOR tNURSING
tPRACTICE
, ABRAMS' tCLINICAL tDRUG tTHERAPY: tRATIONALES tFOR tNURSING
tPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
t t t t t t t t
1. A twoman tdiagnosed twith tobsessive–compulsive tdisorder thas tbeen tprescribed
toral t paroxetine thydrochloride. tWhat t is tthe texpected teffect t for tthis
tprescription?
A. Curative teffect ton tsymptoms
B. Systemic teffect ton tsymptoms
C. Local teffect ton tsymptoms
D. Parenteral teffect ton tsymptoms
ANS: t tB
Rationale: tDrugs tthat tproduce tsystemic teffects tare ttaken tinto tthe tbody, tcirculated tthrough
t the tbloodstream tto ttheir t sites tof taction tin tvarious tbody ttissues, t and teventually teliminated
t from tthe tbody. t Curative tagents tare tgiven tto t cure ta tdisease tprocess. t In tthis tcase,
t paroxetine t hydrochloride twill tcontrol tthe tsymptoms tbut t not tcure tthe tdisorder. tDrugs twith
t local teffects, t such tas tsunscreen tand t local tanesthetics, tact tmainly tat tthe tsite tof tapplication.
t Paroxetine t hydrochloride t is tnot tadministered tparenterally. t Parenteral tagents tare
tadministered t subcutaneously, t intramuscularly, t or tintravenously.
PTS: 1 REF: p. t3, tIntroduction OBJ: 1
NAT: t Client tNeeds: tPhysiological tIntegrity: tPharmacological tand tParenteral tTherapies
t TOP: Chapter: t1: tThe tFoundation tof tPharmacology: t Quality tand tSafety
KEY: t Integrated tProcess: tNursing tProcess
BLM: t t Cognitive tLevel: tUnderstand NOT: t Multiple tChoice
2. A tclient thas tbeen tprescribed tan tantibiotic. tThis tmedication tis ta tnaturally toccurring
substance tthat thas tbeen tcheGmRicA
alDlyEm
SoBdOifOieSd.TWhaOttM
.C is tanother tname tfor tthis ttype tof
tmedication?
A. Synthetic tdrug
B. Semisynthetic tdrug
C. Biotechnology tdrug
D. Prototype tdrug
ANS: t tB
Rationale: tSemisynthetic tdrugs t(e.g., tmany tantibiotics) tare tnaturally toccurring tsubstances
t that thave tbeen tchemically tmodified. tSynthetic tdrugs tare tmore tstandardized t in ttheir
t chemical t characteristics, t more tconsistent t in ttheir teffects, tand tless t likely tto t produce
tallergic treactions. t Biotechnology tdrugs t involve t manipulating tDNA tand tRNA tand
trecombining tgenes t into t hybrid t molecules tthat t can tbe t inserted tinto tliving torganisms.
t Prototype tdrugs tare tthe tfirst t drug tof ta tparticular t group tto t be tdeveloped.
PTS: 1 REF: p. t3, tDrug tSources OBJ: 1
NAT: t Client tNeeds: tPhysiological tIntegrity: tPharmacological tand tParenteral tTherapies
t TOP: Chapter: t1: tThe tFoundation tof tPharmacology: tQuality tand tSafety
KEY: t Integrated tProcess: tNursing tProcess
BLM: t t Cognitive tLevel: tUnderstand NOT: t Multiple tChoice
3. Which tclassification tapplies tto tmorphine?
A. Central tnervous tsystem tdepressant
B. Central tnervous tsystem tstimulant
ABRAMS' t CLINICAL tDRUG tTHERAPY: t RATIONALES tFOR tNURSING tPRACTICE
,ABRAMS' tCLINICAL tDRUG tTHERAPY: tRATIONALES tFOR tNURSING
tPRACTICE
,ABRAMS' tCLINICAL tDRUG tTHERAPY: tRATIONALES tFOR tNURSING
tPRACTICE
, ABRAMS' tCLINICAL tDRUG tTHERAPY: tRATIONALES tFOR tNURSING
tPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
t t t t t t t t
1. A twoman tdiagnosed twith tobsessive–compulsive tdisorder thas tbeen tprescribed
toral t paroxetine thydrochloride. tWhat t is tthe texpected teffect t for tthis
tprescription?
A. Curative teffect ton tsymptoms
B. Systemic teffect ton tsymptoms
C. Local teffect ton tsymptoms
D. Parenteral teffect ton tsymptoms
ANS: t tB
Rationale: tDrugs tthat tproduce tsystemic teffects tare ttaken tinto tthe tbody, tcirculated tthrough
t the tbloodstream tto ttheir t sites tof taction tin tvarious tbody ttissues, t and teventually teliminated
t from tthe tbody. t Curative tagents tare tgiven tto t cure ta tdisease tprocess. t In tthis tcase,
t paroxetine t hydrochloride twill tcontrol tthe tsymptoms tbut t not tcure tthe tdisorder. tDrugs twith
t local teffects, t such tas tsunscreen tand t local tanesthetics, tact tmainly tat tthe tsite tof tapplication.
t Paroxetine t hydrochloride t is tnot tadministered tparenterally. t Parenteral tagents tare
tadministered t subcutaneously, t intramuscularly, t or tintravenously.
PTS: 1 REF: p. t3, tIntroduction OBJ: 1
NAT: t Client tNeeds: tPhysiological tIntegrity: tPharmacological tand tParenteral tTherapies
t TOP: Chapter: t1: tThe tFoundation tof tPharmacology: t Quality tand tSafety
KEY: t Integrated tProcess: tNursing tProcess
BLM: t t Cognitive tLevel: tUnderstand NOT: t Multiple tChoice
2. A tclient thas tbeen tprescribed tan tantibiotic. tThis tmedication tis ta tnaturally toccurring
substance tthat thas tbeen tcheGmRicA
alDlyEm
SoBdOifOieSd.TWhaOttM
.C is tanother tname tfor tthis ttype tof
tmedication?
A. Synthetic tdrug
B. Semisynthetic tdrug
C. Biotechnology tdrug
D. Prototype tdrug
ANS: t tB
Rationale: tSemisynthetic tdrugs t(e.g., tmany tantibiotics) tare tnaturally toccurring tsubstances
t that thave tbeen tchemically tmodified. tSynthetic tdrugs tare tmore tstandardized t in ttheir
t chemical t characteristics, t more tconsistent t in ttheir teffects, tand tless t likely tto t produce
tallergic treactions. t Biotechnology tdrugs t involve t manipulating tDNA tand tRNA tand
trecombining tgenes t into t hybrid t molecules tthat t can tbe t inserted tinto tliving torganisms.
t Prototype tdrugs tare tthe tfirst t drug tof ta tparticular t group tto t be tdeveloped.
PTS: 1 REF: p. t3, tDrug tSources OBJ: 1
NAT: t Client tNeeds: tPhysiological tIntegrity: tPharmacological tand tParenteral tTherapies
t TOP: Chapter: t1: tThe tFoundation tof tPharmacology: tQuality tand tSafety
KEY: t Integrated tProcess: tNursing tProcess
BLM: t t Cognitive tLevel: tUnderstand NOT: t Multiple tChoice
3. Which tclassification tapplies tto tmorphine?
A. Central tnervous tsystem tdepressant
B. Central tnervous tsystem tstimulant
ABRAMS' t CLINICAL tDRUG tTHERAPY: t RATIONALES tFOR tNURSING tPRACTICE
